Núria Reig

Biography

 Núria Reig is a Biochemist with a solid research experience both in the academic and the industrial settings.  After a PhD in Biochemistry and Molecular Biology at the University of Barcelona, she moved to Switzerland for postdoc studies in the field of host-pathogen interactions and immunology at the École Polytechnique Fédérale de Lausanne (Switzerland), with a long-standing collaboration with Yale University (CT, USA).  She then joined Xigen SA, a Swiss biotechnology company specialized in inflammation, as Senior Scientist in Discovery Research.  She contributed to the development of XG104 and brimapitide, currently in Phase 2 and Phase 3 development for ocular indications, respectively. Ms Reig joined SOM Biotech in 2010 initially as project manager and later as R&D Manager.  Among the different projects she has been involved in at SOM Biotech, she has been responsible for the development of SOM0226, a repositioned compound for the treatment of Transthyretin Amyloidosis that was successfully licensed after a Phase 2 proof of concept study. She has managed the company IP portfolio and contributed to 5 patents, 12 research and review articles and 11 presentations in international meetings. 

Research Interest

 Biochemistry